GGrantIndex
← Search

Tissue Acquisition And Cellular/Molecular Analysis Shared Resource (TACMASR)

$237,191P30FY2023CANIH

University Of Arizona, Tucson AZ

Investigators

Linked publications, trials & patents

Paper 39631050Paper 39622842Paper 39612086Paper 39361227Paper 39312766Paper 39151774Paper 39100646Paper 39075233Paper 38875929Paper 38858600Paper 38826434Paper 38804255Paper 38769192Paper 38759377Paper 38729260Paper 38719743Paper 38715255Paper 38687603Paper 38658768Paper 38639990Paper 38613866Paper 38612480Paper 38474232Paper 38464045Paper 38453918Paper 38386696Paper 38386396Paper 38328594Paper 38313301Paper 38309054Paper 38291312Paper 38215755Paper 38203706Paper 38199366Paper 38164625Paper 38164604Paper 38097734Paper 38097593Paper 38096366Trial NCT07214506Trial NCT06009926Trial NCT05699603Trial NCT05237960Trial NCT05121051Trial NCT04530552Trial NCT03708055Trial NCT03602066Trial NCT03601507Trial NCT03578432Trial NCT03422536Trial NCT03402230Trial NCT03376971Trial NCT03365895Trial NCT03196180Trial NCT02581137Trial NCT02568566Trial NCT02348203Trial NCT02326805Trial NCT02123849Trial NCT01686165Trial NCT01433913Trial NCT01394211Trial NCT01385280Trial NCT01370889Trial NCT01288261Trial NCT01172028Trial NCT01097304Trial NCT01077453Trial NCT00980395Trial NCT00978718Trial NCT00900432Trial NCT00900341Trial NCT00898703Trial NCT00896935Trial NCT00892268Trial NCT00841204Trial NCT00752739Trial NCT00732498Trial NCT00721877Trial NCT00702299Trial NCT00701857Trial NCT00699907Trial NCT00619060Trial NCT00608634Trial NCT00601640Trial NCT00410618Trial NCT00373022Trial NCT00363805Trial NCT00303823Trial NCT00245024Trial NCT00091325Trial NCT00078897Trial NCT00003307Trial NCT00003082Patent 9486545Patent 9435812Patent 9415110Patent 9262824Patent 5650489Patent 5510240

Abstract

TISSUE ACQUISITION & CELLULAR/MOLECULAR ANALYSIS: ABSTRACT Personalized treatment of cancer is rapidly becoming a standard practice. Several factors contribute to the uniqueness of a patient, including the individual’s genome, the genome and epigenome of the cancer, disease presentation, gender, exposures, lifestyle, microbiome, and other comorbidities. The identification of specific biomarkers, signaling pathways, immune cell signatures and genetic mutations within tumors underlies molecular targeted therapies and new insights into cancer treatment. Projects require tissue samples of human tumors, which may be implanted in mouse models or used for the generation of organotypic cultures that duplicate the human disease progression and response to treatment. New drug treatments will first be tested in these preclinical models using patient samples before developed therapeutic approaches reach clinical trials. In addition, deciphering genetic alterations and aberrant and tumor-related genes are used for biomarkers for targeted therapies that is unique to that patient. The overall goal of the Tissue Acquisition & Cellular/Molecular Analysis Shared Resource (TACMASR) is to foster individualized approaches for the early detection and therapy of cancers utilizing a new dimension of research pathology for biomarker/drug discovery, digital and spatial imaging, and innovative morphological analysis of 3D cultures. Through continued emphasis on advancing clinical and translational research and increasing collaborations among basic and clinical investigators, TACMASR serves as a centralized resource, providing University of Arizona Cancer Center (UACC) Members with access to clinically annotated, high-quality human specimens. TACMASR offers a comprehensive biorepository coupled with advanced human and animal tissue analysis using state-of-the art microscopy, 3D organotypic cultures, and expert analysis and interpretation of results by well trained staff. The Specific Aims of TACMASR are to: (1) provide biospecimens with a seamless process for the collection, processing, banking, and distribution of human tissues; (2) support a full service research histology laboratory that offers routine and specialized paraffin embedding, sectioning, automated hematoxylin and eosin staining, frozen sectioning, and a large selection of special stains; and (3) develop new protocols and state-of-the-art technologies to meet the special needs of requesting investigators and foster individualized approaches for the early detection and therapy of cancers. In CY20, TACMASR provided services to 81 unique users (53% UACC Members). Services since 2016 have contributed to 47 publications by UACC Members and 29 grants.

View original record on NIH RePORTER →